315 related articles for article (PubMed ID: 23770387)
1. Chaperone-mediated gene therapy with recombinant AAV-PPCA in a new mouse model of type I sialidosis.
Bonten EJ; Yogalingam G; Hu H; Gomero E; van de Vlekkert D; d'Azzo A
Biochim Biophys Acta; 2013 Oct; 1832(10):1784-92. PubMed ID: 23770387
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy corrects the neurological deficits of mice with sialidosis.
Hwu WL; Chang K; Liu YH; Wang HC; Lee NC; Chien YH
Gene Ther; 2024 May; 31(5-6):263-272. PubMed ID: 38321198
[TBL] [Abstract][Full Text] [Related]
3. Elimination of abnormal sialylglycoproteins in fibroblasts with sialidosis and galactosialidosis by normal gene transfer and enzyme replacement.
Oheda Y; Kotani M; Murata M; Sakuraba H; Kadota Y; Tatano Y; Kuwahara J; Itoh K
Glycobiology; 2006 Apr; 16(4):271-80. PubMed ID: 16361247
[TBL] [Abstract][Full Text] [Related]
4. Short-term, high dose enzyme replacement therapy in sialidosis mice.
Wang D; Bonten EJ; Yogalingam G; Mann L; d'Azzo A
Mol Genet Metab; 2005 Jul; 85(3):181-9. PubMed ID: 15979029
[TBL] [Abstract][Full Text] [Related]
5. Lysosomal sialidase NEU1, its intracellular properties, deficiency, and use as a therapeutic agent.
Itoh K; Tsukimoto J
Glycoconj J; 2023 Dec; 40(6):611-619. PubMed ID: 38147151
[TBL] [Abstract][Full Text] [Related]
6. Heterodimerization of the sialidase NEU1 with the chaperone protective protein/cathepsin A prevents its premature oligomerization.
Bonten EJ; Campos Y; Zaitsev V; Nourse A; Waddell B; Lewis W; Taylor G; d'Azzo A
J Biol Chem; 2009 Oct; 284(41):28430-28441. PubMed ID: 19666471
[TBL] [Abstract][Full Text] [Related]
7. Conventional and Unconventional Therapeutic Strategies for Sialidosis Type I.
Mosca R; van de Vlekkert D; Campos Y; Fremuth LE; Cadaoas J; Koppaka V; Kakkis E; Tifft C; Toro C; Allievi S; Gellera C; Canafoglia L; Visser G; Annunziata I; d'Azzo A
J Clin Med; 2020 Mar; 9(3):. PubMed ID: 32143456
[TBL] [Abstract][Full Text] [Related]
8. Intermittent enzyme replacement therapy with recombinant human β-galactosidase prevents neuraminidase 1 deficiency.
Luu AR; Wong C; Agrawal V; Wise N; Handyside B; Lo MJ; Pacheco G; Felix JB; Giaramita A; d'Azzo A; Vincelette J; Bullens S; Bunting S; Christianson TM; Hague CM; LeBowitz JH; Yogalingam G
J Biol Chem; 2020 Sep; 295(39):13556-13569. PubMed ID: 32727849
[TBL] [Abstract][Full Text] [Related]
9. Protective protein/cathepsin A rescues N-glycosylation defects in neuraminidase-1.
Wang D; Zaitsev S; Taylor G; d'Azzo A; Bonten E
Biochim Biophys Acta; 2009 Apr; 1790(4):275-82. PubMed ID: 19714866
[TBL] [Abstract][Full Text] [Related]
10. AAV-mediated gene therapy for Sialidosis.
van de Vlekkert D; Hu H; Fremuth LE; Brown SA; Weesner JA; Gomero E; Campos Y; d'Azzo A
bioRxiv; 2023 Nov; ():. PubMed ID: 38014061
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis, Emerging therapeutic targets and Treatment in Sialidosis.
d'Azzo A; Machado E; Annunziata I
Expert Opin Orphan Drugs; 2015; 3(5):491-504. PubMed ID: 26949572
[TBL] [Abstract][Full Text] [Related]
12. Preclinical dose-finding study with a liver-tropic, recombinant AAV-2/8 vector in the mouse model of galactosialidosis.
Hu H; Gomero E; Bonten E; Gray JT; Allay J; Wu Y; Wu J; Calabrese C; Nienhuis A; d'Azzo A
Mol Ther; 2012 Feb; 20(2):267-74. PubMed ID: 22008912
[TBL] [Abstract][Full Text] [Related]
13. Functional amelioration of murine galactosialidosis by genetically modified bone marrow hematopoietic progenitor cells.
Leimig T; Mann L; Martin Mdel P; Bonten E; Persons D; Knowles J; Allay JA; Cunningham J; Nienhuis AW; Smeyne R; d'Azzo A
Blood; 2002 May; 99(9):3169-78. PubMed ID: 11964280
[TBL] [Abstract][Full Text] [Related]
14. Type I sialidosis, a normosomatic lysosomal disease, in the differential diagnosis of late-onset ataxia and myoclonus: An overview.
Caciotti A; Melani F; Tonin R; Cellai L; Catarzi S; Procopio E; Chilleri C; Mavridou I; Michelakakis H; Fioravanti A; d'Azzo A; Guerrini R; Morrone A
Mol Genet Metab; 2020 Feb; 129(2):47-58. PubMed ID: 31711734
[TBL] [Abstract][Full Text] [Related]
15. Galactosialidosis: preclinical enzyme replacement therapy in a mouse model of the disease, a proof of concept.
Cadaoas J; Hu H; Boyle G; Gomero E; Mosca R; Jayashankar K; Machado M; Cullen S; Guzman B; van de Vlekkert D; Annunziata I; Vellard M; Kakkis E; Koppaka V; d'Azzo A
Mol Ther Methods Clin Dev; 2021 Mar; 20():191-203. PubMed ID: 33426146
[TBL] [Abstract][Full Text] [Related]
16. Modeling Sialidosis with Neural Precursor Cells Derived from Patient-Derived Induced Pluripotent Stem Cells.
Seol B; Kim YD; Cho YS
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922276
[TBL] [Abstract][Full Text] [Related]
17. Neu4, a novel human lysosomal lumen sialidase, confers normal phenotype to sialidosis and galactosialidosis cells.
Seyrantepe V; Landry K; Trudel S; Hassan JA; Morales CR; Pshezhetsky AV
J Biol Chem; 2004 Aug; 279(35):37021-9. PubMed ID: 15213228
[TBL] [Abstract][Full Text] [Related]
18. Type 1 Sialidosis Patient With a Novel Deletion Mutation in the NEU1 Gene: Case Report and Literature Review.
Ahn JH; Kim AR; Lee C; Kim NKD; Kim NS; Park WY; Kim M; Youn J; Cho JW; Kim JS
Cerebellum; 2019 Jun; 18(3):659-664. PubMed ID: 30635863
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathology of NEU1 gene in sialidosis.
Seyrantepe V; Poupetova H; Froissart R; Zabot MT; Maire I; Pshezhetsky AV
Hum Mutat; 2003 Nov; 22(5):343-52. PubMed ID: 14517945
[TBL] [Abstract][Full Text] [Related]
20. Clinical and electrophysiological characteristics of a type 1 sialidosis patient with a novel deletion mutation in NEU1 gene.
Fan SP; Lee NC; Lin CH
J Formos Med Assoc; 2020 Jan; 119(1 Pt 3):406-412. PubMed ID: 31371146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
